@article{Buthelezi2023,
abstract = {Infectious diseases, particularly Tuberculosis (TB) caused by Mycobacterium tuberculosis, pose a significant global health challenge, with 1.6 million reported deaths in 2021, making it the most fatal disease caused by a single infectious agent. The rise of drug-resistant infectious diseases adds to the urgency of finding effective and safe intervention therapies. Antisense therapy uses antisense oligonucleotides (ASOs) that are short, chemically modified, single-stranded deoxyribonucleotide molecules complementary to their mRNA target. Due to their designed target specificity and inhibition of a disease-causing gene at the mRNA level, antisense therapy has gained interest as a potential therapeutic approach. This type of therapy is currently utilized in numerous diseases, such as cancer and genetic disorders. Currently, there are limited but steadily increasing studies available that report on the use of ASOs as treatment for infectious diseases. This review explores the sustainability of FDA-approved and preclinically tested ASOs as a treatment for infectious diseases and the adaptability of ASOs for chemical modifications resulting in reduced side effects with improved drug delivery; thus, highlighting the potential therapeutic uses of ASOs for treating infectious diseases.},
author = {Buthelezi, Lwanda Abonga and Pillay, Shandre and Ntuli, Noxolo Nokukhanya and Gcanga, Lorna and Guler, Reto},
doi = {10.3390/CELLS12162119},
file = {:C$\backslash$:/Users/01462563/AppData/Local/Mendeley Ltd./Mendeley Desktop/Downloaded/Buthelezi et al. - 2023 - Antisense therapy for infectious diseases.pdf:pdf},
issn = {2073-4409},
journal = {Cells},
keywords = {OA,OA{\_}PMC,antisense oligonucleotide,antisense therapy,fund{\_}ack,infectious disease,mRNA,review},
mendeley-tags = {OA,OA{\_}PMC,fund{\_}ack,review},
month = {aug},
number = {16},
pages = {2119},
pmid = {37626929},
publisher = {Multidisciplinary Digital Publishing Institute},
title = {{Antisense therapy for infectious diseases}},
url = {https://www.mdpi.com/2073-4409/12/16/2119/htm https://www.mdpi.com/2073-4409/12/16/2119},
volume = {12},
year = {2023}
}

{"_id":"7oP8Y3iD5eFxNTAzu","bibbaseid":"buthelezi-pillay-ntuli-gcanga-guler-antisensetherapyforinfectiousdiseases-2023","author_short":["Buthelezi, L. A.","Pillay, S.","Ntuli, N. N.","Gcanga, L.","Guler, R."],"bibdata":{"bibtype":"article","type":"article","abstract":"Infectious diseases, particularly Tuberculosis (TB) caused by Mycobacterium tuberculosis, pose a significant global health challenge, with 1.6 million reported deaths in 2021, making it the most fatal disease caused by a single infectious agent. The rise of drug-resistant infectious diseases adds to the urgency of finding effective and safe intervention therapies. Antisense therapy uses antisense oligonucleotides (ASOs) that are short, chemically modified, single-stranded deoxyribonucleotide molecules complementary to their mRNA target. Due to their designed target specificity and inhibition of a disease-causing gene at the mRNA level, antisense therapy has gained interest as a potential therapeutic approach. This type of therapy is currently utilized in numerous diseases, such as cancer and genetic disorders. Currently, there are limited but steadily increasing studies available that report on the use of ASOs as treatment for infectious diseases. This review explores the sustainability of FDA-approved and preclinically tested ASOs as a treatment for infectious diseases and the adaptability of ASOs for chemical modifications resulting in reduced side effects with improved drug delivery; thus, highlighting the potential therapeutic uses of ASOs for treating infectious diseases.","author":[{"propositions":[],"lastnames":["Buthelezi"],"firstnames":["Lwanda","Abonga"],"suffixes":[]},{"propositions":[],"lastnames":["Pillay"],"firstnames":["Shandre"],"suffixes":[]},{"propositions":[],"lastnames":["Ntuli"],"firstnames":["Noxolo","Nokukhanya"],"suffixes":[]},{"propositions":[],"lastnames":["Gcanga"],"firstnames":["Lorna"],"suffixes":[]},{"propositions":[],"lastnames":["Guler"],"firstnames":["Reto"],"suffixes":[]}],"doi":"10.3390/CELLS12162119","file":":C$\\$:/Users/01462563/AppData/Local/Mendeley Ltd./Mendeley Desktop/Downloaded/Buthelezi et al. - 2023 - Antisense therapy for infectious diseases.pdf:pdf","issn":"2073-4409","journal":"Cells","keywords":"OA,OA_PMC,antisense oligonucleotide,antisense therapy,fund_ack,infectious disease,mRNA,review","mendeley-tags":"OA,OA_PMC,fund_ack,review","month":"aug","number":"16","pages":"2119","pmid":"37626929","publisher":"Multidisciplinary Digital Publishing Institute","title":"Antisense therapy for infectious diseases","url":"https://www.mdpi.com/2073-4409/12/16/2119/htm https://www.mdpi.com/2073-4409/12/16/2119","volume":"12","year":"2023","bibtex":"@article{Buthelezi2023,\r\nabstract = {Infectious diseases, particularly Tuberculosis (TB) caused by Mycobacterium tuberculosis, pose a significant global health challenge, with 1.6 million reported deaths in 2021, making it the most fatal disease caused by a single infectious agent. The rise of drug-resistant infectious diseases adds to the urgency of finding effective and safe intervention therapies. Antisense therapy uses antisense oligonucleotides (ASOs) that are short, chemically modified, single-stranded deoxyribonucleotide molecules complementary to their mRNA target. Due to their designed target specificity and inhibition of a disease-causing gene at the mRNA level, antisense therapy has gained interest as a potential therapeutic approach. This type of therapy is currently utilized in numerous diseases, such as cancer and genetic disorders. Currently, there are limited but steadily increasing studies available that report on the use of ASOs as treatment for infectious diseases. This review explores the sustainability of FDA-approved and preclinically tested ASOs as a treatment for infectious diseases and the adaptability of ASOs for chemical modifications resulting in reduced side effects with improved drug delivery; thus, highlighting the potential therapeutic uses of ASOs for treating infectious diseases.},\r\nauthor = {Buthelezi, Lwanda Abonga and Pillay, Shandre and Ntuli, Noxolo Nokukhanya and Gcanga, Lorna and Guler, Reto},\r\ndoi = {10.3390/CELLS12162119},\r\nfile = {:C$\\backslash$:/Users/01462563/AppData/Local/Mendeley Ltd./Mendeley Desktop/Downloaded/Buthelezi et al. - 2023 - Antisense therapy for infectious diseases.pdf:pdf},\r\nissn = {2073-4409},\r\njournal = {Cells},\r\nkeywords = {OA,OA{\\_}PMC,antisense oligonucleotide,antisense therapy,fund{\\_}ack,infectious disease,mRNA,review},\r\nmendeley-tags = {OA,OA{\\_}PMC,fund{\\_}ack,review},\r\nmonth = {aug},\r\nnumber = {16},\r\npages = {2119},\r\npmid = {37626929},\r\npublisher = {Multidisciplinary Digital Publishing Institute},\r\ntitle = {{Antisense therapy for infectious diseases}},\r\nurl = {https://www.mdpi.com/2073-4409/12/16/2119/htm https://www.mdpi.com/2073-4409/12/16/2119},\r\nvolume = {12},\r\nyear = {2023}\r\n}\r\n","author_short":["Buthelezi, L. A.","Pillay, S.","Ntuli, N. N.","Gcanga, L.","Guler, R."],"key":"Buthelezi2023","id":"Buthelezi2023","bibbaseid":"buthelezi-pillay-ntuli-gcanga-guler-antisensetherapyforinfectiousdiseases-2023","role":"author","urls":{"Paper":"https://www.mdpi.com/2073-4409/12/16/2119/htm https://www.mdpi.com/2073-4409/12/16/2119"},"keyword":["OA","OA_PMC","antisense oligonucleotide","antisense therapy","fund_ack","infectious disease","mRNA","review"],"metadata":{"authorlinks":{}}},"bibtype":"article","biburl":"https://drive.google.com/uc?export=download&id=1-JLqZ7RwZ3VC2d6ErLGHAtOeMRS_7GCz","dataSources":["KmoiX2LKn8hjsLMkh","XbBjMG3Fzj4C9dGTw","Krmt6gt9ktB2s6ARh"],"keywords":["oa","oa_pmc","antisense oligonucleotide","antisense therapy","fund_ack","infectious disease","mrna","review"],"search_terms":["antisense","therapy","infectious","diseases","buthelezi","pillay","ntuli","gcanga","guler"],"title":"Antisense therapy for infectious diseases","year":2023}